Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now

Judgment Day has come for Amgen’s first-in-class KRAS inhibitor Lumakras as the FDA’s Oncologic Drugs Advisory Committee (ODAC) gathered Thursday to weigh the merits of the cancer med’s phase 3 clinical trial CodeBreak 200. But, despite a negative vote for Amgen, it appears Lumakras is likely to hold onto its accelerated approval—for now.